




The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 167% points. The greatest weakness of Filana Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 332%, being 119% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	129,633
Cost of Goods Sold	0
Intangible Assets	176
Liabilities, Current	14,195
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	8,740
Other Revenues	0
Property and Equipment	21,854
Research and Development	89,423
Selling, General and Administrative Expense	16,534

Output Variable	Value in 1000 USD
Assets	151,663
Liabilities	14,195
Expenses	105,957
Revenues	0
Stockholders Equity	137,468
Net Income	-97,217
Comprehensive Net Income	-97,217
BaseVar	140,278
ECR before LimitedLiability	244%
Economic Capital Ratio	332%